Savings from biosimilars may be undercut by prescribing bias: Poll

A potential stumbling block to realizing potential savings from lower-cost biosimilar medications could be doctor reticence to prescribe them, a recent study finds, Fierce Pharma reports. A recent survey of 1,200 doctors on Sermo – a social media network for physicians – found that 77% do not favor the ability of pharmacists to freely switch patients from reference products to biosimilars. They want patients to be given exactly what they prescribe, the survey showed.